Atara Biotherapeutics Inc (ATRA)

Currency in USD
13.0200
+1.5200(+13.22%)
Closed·
After Hours
13.0000-0.0200(-0.15%)
·
ATRA Scorecard
Full Analysis
Net income is expected to grow this year
Unusual trading volume
Fair Value
Day's Range
11.580013.2099
52 wk Range
5.005018.7050
Key Statistics
Prev. Close
11.5
Open
11.58
Day's Range
11.58-13.2099
52 wk Range
5.005-18.705
Volume
149.88K
Average Volume (3m)
59.77K
1-Year Change
28.53%
Book Value / Share
-9.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.0000
Upside
+22.89%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Atara Biotherapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Atara Biotherapeutics Inc Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Compare ATRA to Peers and Sector

Metrics to compare
ATRA
Peers
Sector
Relationship
P/E Ratio
−5.7x−4.8x−0.5x
PEG Ratio
−0.050.000.00
Price/Book
−1.6x6.2x2.6x
Price / LTM Sales
0.4x8.6x3.2x
Upside (Analyst Target)
47.8%123.2%42.7%
Fair Value Upside
Unlock18.0%5.8%Unlock

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.0000
(+22.89% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
3.50 / -0.27
Revenue / Forecast
98.15M / --
EPS Revisions
Last 90 days

ATRA Income Statement

People Also Watch

245.47
BIO
+0.50%
2.250
APYX
+0.45%
14.96
ARWR
+1.70%
87.80
QRVO
-0.15%

FAQ

What Stock Exchange Does Atara Biotherapeutics Inc Trade On?

Atara Biotherapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Atara Biotherapeutics Inc?

The stock symbol for Atara Biotherapeutics Inc is "ATRA."

What Is the Atara Biotherapeutics Inc Market Cap?

As of today, Atara Biotherapeutics Inc market cap is 88.48M.

What Is Atara Biotherapeutics Inc's Earnings Per Share (TTM)?

The Atara Biotherapeutics Inc EPS (TTM) is -1.78.

From a Technical Analysis Perspective, Is ATRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Atara Biotherapeutics Inc Stock Split?

Atara Biotherapeutics Inc has split 1 times.

How Many Employees Does Atara Biotherapeutics Inc Have?

Atara Biotherapeutics Inc has 89 employees.

What is the current trading status of Atara Biotherapeutics Inc (ATRA)?

As of 23 Jul 2025, Atara Biotherapeutics Inc (ATRA) is trading at a price of 13.02, with a previous close of 11.50. The stock has fluctuated within a day range of 11.58 to 13.21, while its 52-week range spans from 5.01 to 18.71.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.